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Abstract
Background: Flow-mediated dilation (FMD) and reactive hyperemia-peripheral arterial tonometry 
(RH-PAT) are both established modalities to assess vascular endothelial function. However, clinical 
significance of FMD and RH-PAT may be different because these methods measure vascular function 
in different vessels (conduit arteries and resistance vessels).
Methods: To elucidate differences in the clinical significance of FMD and RH-PAT,  a simultaneous 
determination of FMD was performed and reactive hyperemia index (RHI) measured by RH-PAT in 131 
consecutive patients who underwent coronary angiography for suspicion of coronary artery disease (CAD).
Results: There was no significant correlation between FMD and RHI in patients overall. When pa-
tients were divided into four groups: FMD ≥ 6%/RHI ≥ 1.67 group, FMD ≥ 6%/RHI < 1.67 group, 
FMD < 6%/RHI ≥ 1.67 group and FMD < 6%/RHI < 1.67 group, the highest incidence of multi-
vessel CAD was seen in the FMD < 6%/RHI < 1.67 group (52%). Multiple logistic regression analysis 
showed that a prevalence of both FMD < 6% and RHI < 1.67 was an independent predictor of multi-
vessel CAD (odds ratio: 4.160, 95% confidence interval: 1.505–11.500, p = 0.006). RHI was negatively 
correlated with the baseline vessel diameter (R = –0.268, p = 0.0065) and maximum vessel diameter  
(R = –0.266, p = 0.0069) in patients with FMD < 6%, whereas these correlations were absent in 
patients with FMD ≥ 6%. 
Conclusions: Present results suggest that noninvasive assessment of vascular endothelial functions 
provide pathophysiological information on both conduit arteries and resistance vessels in patients with 
CAD. (Cardiol J XXXX; XX, X: xx–xx)
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Introduction
The endothelium plays a seminal role in the 
regulation of vascular tone, new vessel growth, 
thrombogenicity, and inflammation [1]. Moreover, 
endothelial dysfunction is associated with car-
diovascular events. Brachial artery flow-mediated 
dilation (FMD) and reactive hyperemia-peripheral 
arterial tonometry (RH-PAT) are established 
methods to assess vascular endothelial function. 
FMD measures the ability of the brachial artery to 
release endothelial nitric oxide (NO) during reac-
tive hyperemia after a 5-min occlusion of the artery 
with a blood pressure cuff [2, 3]. Celermajer et al. 
[4] first observed this response in vivo by using 
ultrasound to measure changes in the diameter 
of the brachial artery, and later demonstrated this 
response to be mainly NO-dependent [5]. Impor-
tantly, peripheral vascular endothelial function as 
assessed by FMD correlates with coronary artery 
endothelial function [6]. In addition, FMD has 
independent prognostic value to predict future 
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cardiovascular events that may exceed the predic-
tive ability of traditional risk factors [7]. On the 
other hand, RH-PAT has been recently introduced 
as a new surrogate marker to evaluate endothelial 
function. RH-PAT is a noninvasive, automatic, 
and quantitative method of clinical assessment 
based on digital measurements of the hyperemic 
response [8]. Although FMD reflects endothelial 
function of large conduit arteries [9]. Reactive 
hyperemia index (RHI) as measured by RH-PAT re-
flects endothelial function of the microvasculature 
(i.e., resistance vessels) [10] and depends more 
on endothelium-derived hyperpolarizing factor 
(EDHF) than NO [11, 12]. However, endothelial 
function measured by RH-PAT also predicts car-
diovascular events [13]. 
Although both FMD and RH-PAT can predict 
cardiovascular events, it was hypothesized that the 
clinical significance of these two vascular endothe-
lial function tests in patients with cardiovascular 
diseases are different because these methods 
measure vascular function in different vessels 
(conduit arteries or resistance vessels). In this 
study, both FMD and RH-PAT-based RHI were 
simultaneously measured in patients with coronary 
artery disease (CAD) to elucidate differences in 
clinical significance of each method for assessment 
of vascular endothelial function. 
Methods
Subjects and study outline
Simultaneous measurement of FMD and RH-
PAT were performed in 131 consecutive patients, 
who underwent diagnostic coronary angiography 
due to suspicion of CAD (including stable angina 
pectoris, old myocardium infarction, coronary 
spastic angina and chest pain syndrome) at Dokkyo 
Medical University Hospital. Patients were exclud-
ed if they had acute coronary syndrome, valvular 
heart disease, atrial fibrillation/flutter, permanent 
pacemaker implantation, impaired left ventricular 
systolic function (left ventricular ejection fraction 
< 40%), aortic dissection, malignancy or serious 
liver diseases, or were on hemodialysis. The Dok-
kyo Medical University review board approved the 
study protocol, and written informed consent was 
obtained from each patient.
Simultaneous measurement  
of FMD and RHI 
Simultaneous measurement of FMD and RHI 
was performed in the morning of the day before 
coronary angiography, according to the method 
previously described by Tomiyama et al. [14]. In 
brief, the subjects were instructed to fast overnight 
and to abstain from alcohol, smoking, caffeine and 
antioxidant vitamins for at least 12 h before the 
measurements. They were asked to rest in the sit-
ting position in a quiet, dark, air-conditioned room 
(22°C to 25°C) for 5 min. Then, they were asked 
again to rest for at least 15 min in the supine posi-
tion in the same room before FMD and RH-PAT 
procedures. Blood pressure was measured in the 
left arm using a mercury sphygmomanometer with 
an appropriately sized cuff and recorded to the near-
est 2 mmHg. After blood pressure was measured, 
a 10-MHz linear array ultrasound transducer (Unex 
EF 18G, UNEX Corp., Nagoya, Japan) was placed 
on the proximal right brachial artery to measure 
FMD, and the manchette was rolled at the fore-
arm. For the RH-PAT procedure (EndoPAT-2000, 
Itamar Medical Ltd., Caesarea, Israel), a peripheral 
arterial tonometry probe was placed on the right 
index finger and a control tonometry probe was also 
placed on the left index finger to eliminate sympa-
thetic nerve effects. The RH-PAT probes were ex-
changed for each patient. For FMD measurement, 
ultrasound longitudinal images were recorded 
at baseline and continuously from 30 s before to 
≥ 2 min after cuff deflation following compression 
with a cuff pressure that was 50 mmHg above the 
systolic blood pressure of the right forearm for 
5 min. The diastolic diameter of the brachial ar-
tery was determined semi-automatically using an 
instrument equipped with software for monitoring 
the brachial artery diameter. FMD was estimated 
as percent change of brachial artery diameter at 
maximal dilation during hyperemia compared with 
the baseline value. In the RH-PAT procedure, the 
RHI value was calculated as the ratio of reactive 
hyperemia between two hands. Moreover, other 
parameters obtained during the FMD procedure 
such as baseline vessel diameter, maximum ves-
sel diameter and blood flow velocity increase 
(maximum blood flow velocity/baseline blood flow 
velocity) were also measured after forearm cuff 
deflation following compression. 
Assessment of the results  
of coronary angiography
The angiographic findings were visually as-
sessed for all atherosclerotic coronary lesions by an 
investigator who was unaware of the study design. 
According to the classification of the American 
Heart Association, the percent diameter stenosis 
was evaluated for each lesion and the lesion loca-
tion was assessed. The number of affected vessels 
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was assessed, considering that ≥ 75% diameter 
stenosis was a significant atherosclerotic coro-
nary lesion. If there were no significant stenotic 
lesions, provocation of coronary artery spasm was 
performed with an intracoronary injection of ace-
tylcholine. Acetylcholine chloride was injected in 
incremental doses of 25 and 50 μg into the right 
coronary artery and of 25, 50, and 100 μg into the 
left coronary artery over 20 s, with at least a 3 min 
interval between each injection. The patients who 
had a positive acetylcholine test were diagnosed 
with coronary spastic angina and those with a nega-
tive acetylcholine test were diagnosed with chest 
pain syndrome. 
Coronary risk factor assessment
Prior to FMD and RH-PAT procedures, in-
formation on coronary risk factors such as hy-
pertension, diabetes, dyslipidemia and smoking 
habit were obtained from each patient, as well as 
information on medication usage. Height and body 
weight were measured, and body mass index (BMI) 
was calculated as body weight (kg)/(height [m])2. 
Blood pressure was measured using a mercury 
sphygmomanometer with an appropriately sized 
cuff and recorded to the nearest 2 mmHg. Just 
after FMD and RH-PAT procedures, peripheral 
blood samples were taken via the antecubital vein. 
Serum creatinine level was measured using an 
enzymatic method, and the estimated glomerular 
filtration rate (eGFR) was calculated by a formula 
provided by the Japanese Society of Nephrology 
Chronic Kidney Disease (CKD) Practice Guide: 
eGFR (mL/min/1.73 m2) = 194 × (serum creatinine 
level [mg/dL])–1.094 × (age [y]) –0.287. The product of 
this equation was multiplied by a correction factor 
of 0.739 for women [15]. Total cholesterol (TC) 
and triglyceride (TG) levels were determined us-
ing enzymatic methods, high-density lipoprotein 
cholesterol (HDL-C) was measured using the 
precipitation method and low-density lipoprotein 
cholesterol (LDL-C) was calculated using the 
Friedewald formula: LDL-C = TC – HDL-C – 
(TG/5). The LDL-C could not be calculated in 
those patients with a triglyceride level over 400 
mg/dL. Hemoglobin A1c was measured by high-
performance liquid chromatography and values 
were expressed according to the National Glyco-
hemoglobin Standardization Program.
Statistical analysis
Data were expressed as the mean ± standard 
deviation (SD) or median and interquartile range. 
Normality for distribution of continuous variables 
was assessed using the Shapiro-Wilk test. Multiple 
group comparisons were performed using one-way 
analysis of variance followed by the post-hoc Bon-
ferroni test for continuous variables and the Fisher 
exact test for categorical variables. Intra-group 
comparisons for normally distributed continu-
ous variables were performed using an unpaired 
t test. The correlation between two variables was 
determined by the Pearson correlation coefficient. 
Logistic regression analysis was performed to 
predict multi-vessel CAD using age, gender, vari-
ous risk factors and vascular endothelial function 
parameters as independent variables. Variables that 
could predict multi-vessel disease using a simple 
logistic regression model were first we determined, 
then multiple regression analysis was performed 
using the variables identified by the simple logistic 
regression model. All statistical analyses were 
performed using the statistical package for Social 
Science (Dr. SPSS II for Windows, SPSS Inc., To-
kyo, Japan). P < 0.05 was considered significant.
Results
Relationship between both values of  
FMD and RHI
In all 131 patients, there was no significant 
correlation between FMD and RHI (R = 0.119). 
Then, the patients were divided into four groups, 
based on cut off values of 6% for FMD and 1.67 for 
RHI, according to previous reports [16, 17], i.e., 
FMD ≥ 6%/RHI ≥ 1.67 group (n = 22; 17%), FMD 
≥ 6%/RHI < 1.67 group (n = 7; 5%), FMD < 6%/
RHI ≥ 1.67 group (n = 81; 62%) and FMD < 6%/
RHI < 1.67 group (n = 21; 6%) (Fig. 1). Baseline 
characteristics were compared among these four 
groups. There were no significant differences 
among the four groups in age, sex, traditional risk 
factors and medications. All patients in groups 
with RHI < 1.67 had significant coronary artery 
stenosis. In the FMD < 6%/RHI ≥ 1.67 group, 86% 
of patients had stable angina. The incidence of old 
myocardial infarction and multi-vessel CAD (≥ 2 
vessels) were both higher in FMD < 6% groups, 
compared with FMD ≥ 6% groups. Among the four 
groups, the highest incidence of multi-vessel CAD 
was seen in the FMD < 6%/RHI < 1.67 group (52% 
of patients in this group) (Table 1). 
Prediction of multi-vessel CAD using  
FMD and RHI
In all 131 patients, multi-vessel CAD was 
seen in 34 (26.0%) patients. Logistic regression 
analysis was performed to try to discriminate the 
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34 multi-vessel CAD patients from the remaining 
97 patients who had no coronary artery stenosis 
or just single-vessel disease. In simple logistic 
regression analysis, age, gender, coronary risk fac-
tors and vascular endothelial function parameters 
to predict multi-vessel disease were used. These 
analyses showed that the prevalence of both FMD 
< 6% and RHI < 1.67 was a significant predictor 
of multi-vessel disease (odds ratio [OR]: 4.161, 
95% confidence interval [CI]: 1.574–10.998, p = 
0.004); and age (OR: 1.026, 95% CI: 0.986–1.067, 
p = 0.206), BMI (OR: 1.077, 95% CI: 0.974–1.190, 
p = 0.149), systolic blood pressure (OR: 1.020, 
95% CI: 0.996–1.045, p = 0.109), hemoglobin 
A1c (OR: 1.439, 95% CI: 0.892–2.322, p = 0.136) 
and eGFR (OR: 0.981, 95% CI: 0.957–1.006, p = 
0.128) were potential predictors (p < 0.3) (Fig. 2). 
Multiple logistic regression analysis using all of 
these variables showed that only the prevalence 
of both FMD < 6% and RHI < 1.67 independently 
predicted multi-vessel CAD (OR: 4.160, 95% CI: 
1.505–11.500, p = 0.006) (Table 2). 
RHI and the other parameters  
measured with FMD
Next, other parameters measured during the 
FMD procedure separately in 29 patients with 
FMD ≥ 6% and 102 patients with FMD < 6% were 
assessed. In the patients with FMD ≥ 6%, there 
were no significant differences in baseline vessel 
diameter, maximum vessel diameter and blood flow 
velocity increase between 22 patients with RHI ≥ 
1.67 and 7 patients with RHI < 1.67. In patients 
with FMD < 6%, there were also no significant 
differences in these other parameters among 81 
patients with RHI ≥ 1.67 and 21 patients with RHI 
< 1.67 (Table 3). However, RHI was negatively 
correlated with the baseline vessel diameter (R = 
–0.268, p = 0.0065) and maximum vessel diameter 
(R = –0.266, p = 0.0069) in the patients with FMD 
< 6%, whereas these correlations were absent in 
patients with FMD ≥ 6% (Fig. 3). 
Discussion
In the present study, it was first demonstrated 
that FMD and RHI were not correlated in patients 
who underwent coronary angiography for the 
suspicion of CAD. Next, patients were divided 
into four groups, based on cut off values of 6% for 
FMD and 1.67 for RHI. As a result, 62% of the 
patients showed FMD < 6% but RHI ≥ 1.67, and 
52% of patients with FMD < 6% and RHI < 1.67 
had multi-vessel CAD. Multiple regression analysis 
showed that the prevalence of both FMD < 6% and 
RHI < 1.67 independently predicted multi-vessel 
CAD. Finally, the relationship was assessed be-
tween other parameters measured during the FMD 
procedure and RHI. As a result, RHI was negatively 
correlated with brachial artery diameter in patients 
0
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Figure 1. The relationship between flow-mediated dilation (FMD) and reactive hyperemia index (RHI) measured by reac-
tive hyperemia-peripheral arterial tonometry in all patients. There was no significant correlation between FMD and RHI. 
Then, patients were divided into four groups, according to cut-off values of 6% for FMD and 1.67 for RHI: FMD ≥ 6%/ 
/RHI ≥ 1.67 group, FMD ≥ 6%/RHI < 1.67 group, FMD < 6%/ RHI ≥ 1.67 group and FMD < 6%/RHI < 1.67 group.
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with low FMD, whereas a correlation was absent 
in patients with normal FMD. 
Flow-mediated dilation and RH-PAT are both 
extremely effective noninvasive methods of evalu-
ating vascular endothelial function, but have some 
physiological and clinical differences that depend 
on the vessels evaluated with each method. There 
are only a few studies that examined the relation-
ship between FMD and RH-PAT based on RHI. 
Dhindsa et al [18]. demonstrated that FMD was 
significantly and positively associated with RHI 
in apparently healthy normotensive subjects. 
The Framingham Heart Study demonstrated that 
FMD and RHI were not correlated in multivariable 
models [19], whereas the Gutenberg Heart Study 
showed a modest correlation [20]. However, in 
both of these studies, FMD, which represents en-
dothelial function of large conduit arteries, and was 
particularly sensitive to impairment by traditional 
risk factors. In contrast, RHI, which represents en-
dothelial function of resistance vessels, was more 
sensitive to metabolic risk factors, such as diabetes 
and obesity. Moreover, endothelial dysfunction in 
the conduit arteries and resistance vessels could 
also reflect different stages of atherosclerosis. 
Endothelial dysfunction in conduit arteries might 
Table 1. Baseline characteristics.
Normal FMD/ 
/normal RHI  
(n = 22)
Normal FMD/ 
/low RHI  
(n = 7)
Low FMD/ 
/normal RHI  
(n = 81)
Low FMD/ 
/low RHI  
(n = 21)
P
Age [years] 64 ± 10 70 ± 7 67 ± 12 69 ± 8 0.413
Male gender 17 (77%) 5 (71%) 62 (77%) 20 (95%) 0.266
Body mass index [kg/m2] 25.2 ± 4.1 25.5 ± 3.3 23.6 ± 3.6 24.8 ± 3.2 0.137
Risk factors:
Hypertension 16 (73%) 5 (71%) 55 (68%) 13 (62%) 0.891
Diabetes 10 (45%) 2 (29%) 36 (44%) 14 (67%) 0.218
Dyslipidemia 19 (83%) 19 (83%) 12 (80%) 12 (80%) 0.207
Smoking 16 (72%) 4 (57%) 53 (65%) 14 (67%) 0.874
Systolic blood pressure [mmHg] 131 ± 17 128 ± 14 134 ± 18 132 ± 14 0.959
LDL-cholesterol [mg/dL] 94 ± 23 79 ± 13 82 ± 23 78 ± 24 0.103
HDL-cholesterol [mg/dL] 48 ± 13 43 ± 12 50 ± 14 45 ± 13 0.911
Triglyceride [mg/dL] 111 ± 75 74 ± 38 88 ± 52 75 ± 57 0.166
Hemoglobin A1c [%] 6.3 ± 0.9 6.1 ± 0.5 6.3 ± 0.8 6.5 ± 0.7 0.700
Creatinine [mg/dL] 0.79 ± 0.16 0.77 ± 0.17 0.8 ± 0.2 0.9 ± 0.2 0.226
eGFR [mL/min/1.73 m2] 75.4 ± 15.1 71.8 ± 9.3 73.1 ± 17.2 67.2 ± 16.6 0.399
Medications:
ACEI/ARBs 8 (36%) 5 (71%) 33 (41%) 7 (33%) 0.090
Sulfonylureas 3 (14%) 0 (0%) 10 (12%) 3 (14%) 0.777
Insulins 1 (5%) 0 (0%) 3 (4%) 0 (0%) 0.762
Statins 16 (73%) 6 (86%) 64 (79%) 21 (100%) 0.096
Basal disease:
Stable angina pectoris 6 (27%) 6 (86%) 21 (68%) 5 (23%) 0.009
Old myocardial infarction 11 (50%) 1 (14%) 48 (59%) 16 (76%) 0.030
Coronary spastic angina 4 (18%) 0 (0%) 7 (9%) 0 (0%) 0.150
Chest pain syndrome 1 (5%) 0 (0%) 5 (6%) 0 (0%) 0.611
Affected vessel number: 
No stenotic lesion 5 (23%) 0 (0%) 12 (15%) 0 (0%) 0.099
Single vessel disease 16 (73%) 4 (57%) 49 (60%) 10 (48%) 0.364
Multi-vessel disease 1 (5%) 3 (43%) 20 (25%) 11 (52%) 0.005
ACEI — angiotensin converting enzyme inhibitors; ARB — angiotensin receptor blocker; eGFR — estimated glomerular filtration rate;  
FMD — flow-mediated dilation; HDL — high density lipoprotein; LDL — low density lipoprotein; RHI — reactive hyperemia index
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be more important in patients with existing ath-
erosclerosis, whereas that in resistance vessels 
might be an early indicator of arteriosclerosis risk 
[19–21]. Recently, Tomiyama et al. [14] found no 
correlation between FMD and RH-PAT when the 
two parameters were measured simultaneously, and 
results were similar to the present results. They 
demonstrated that autonomic nervous activation, 
especially sympathetic nerve activation induced by 
reactive hyperemia, affected RHI more than FMD. 
Table 3. Other parameters measured during flow-mediated dilation (FMD) procedure.
FMD ≥ 6% (n = 29) FMD < 6% (n = 102)
RHI ≥ 1.67  
(n = 22)
RHI < 1.67  
(n = 7)
P RHI ≥ 1.67  
(n = 81)
RHI < 1.67  
(n = 21)
P
Baseline vessel diameter [mm] 3.93 ± 0.53 3.69 ± 0.60 0.313 4.31 ± 0.56 4.46 ± 0.64 0.313
Maximum vessel diameter [mm] 4.21 ± 0.56 3.95 ± 0.63 0.314 4.47 ± 0.57 4.60 ± 0.64 0.380
Blood flow velocity increase 5.68 ± 2.42 4.17 ± 1.46 0.133 4.83 ± 2.00 4.93 ± 2.55 0.844
RHI — reactive hyperemia index
0 1 2 3 4 5 6 7 8 9 10
Odds ratio (95% condence interval)
P = 0.206
P = 0.625
P = 0.149
P = 0.109
P = 0.136
P = 0.420
P = 0.766
P = 0.895
P = 0.569
P = 0.128
P = 0.739
P = 0.004
Age [year]
Gender [male]
2
Body mass index [kg/m ]
Blood pressure [mmHg]
Hemoglobin A1c [%]
LDL-cholesterol [mg/dL]
HDL-cholesterol [mg/dL]
Trigliceride [mg/dL]
Creatinine [mg/dL]
2
eGFR [mL/min/1.73 m ]
Smoking [yes]
FMD < 6%/RHI < 1.67, yes
Figure 2. Simple logistic regression model to determine variables that predicted multi-vessel coronary artery disease. 
The prevalence of both flow-mediated dilation (FMD) < 6% and reactive hyperemia index (RHI) < 1.67 was a signifi-
cant predictor of multi-vessel disease; age, body mass index, systolic blood pressure, hemoglobin A1c and estimated 
glomerular filtration rate (eGFR) were also potential predictors of multi-vessel disease; HDL — high density lipoprotein; 
LDL — low density lipoprotein.
Table 2. Multiple logistic regression analysis for prediction of multi-vessel coronary artery disease.
Wald l2 Odds ratio 95% CI P
Age [years] 0.609 1.002 0.968–1.079 0.435
Body mass index [kg/m2] 1.151 1.068 0.947–1.204 0.283
Systolic blood pressure [mmHg] 1.133 1.016 0.987–1.045 0.287
Hemoglobin A1c [%] 1.200 1.346 0.791–2.289 0.273
eGFR [mL/min/1.73 m2] 0.183 0.993 0.964–1.024 0.669
FMD < 6%/RHI < 1.67, yes 7.549 4.160 1.505–11.500 0.006
CI — confidence interval; eGFR — estimated glomerular filtration rate; FMD — flow-mediated dilation; RHI — reactive hyperemia index
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Although the relationship between FMD and 
RHI is controversial as described above, there was 
no correlation between these two parameters In 
all patients in the present study. However, analysis 
herein, after dividing patients into four groups pro-
vided some new information. Patients with stenotic 
lesions (i.e., coronary spastic angina or chest pain 
syndrome) were present in groups with low RHI. In 
addition, the highest incidence of multi-vessel CAD 
was seen in the group with the prevalence of both 
FMD < 6% and RHI < 1.67. This result suggests 
that the presence of low values of both FMD and 
RHI would be a strong risk factor for severe CAD. 
Furthermore, multiple regression analysis showed 
that the incidence of both FMD < 6% and RHI 
< 1.67 could independently predict multi-vessel 
CAD also supports this suggestion. Woo et al. [22] 
compared FMD and RHI in patients with CAD and 
demonstrated that the value of each parameter was 
significantly lower in patients with multi-vessel and 
complex CAD. Their receiver-operating character-
istic curve analysis showed that both FMD and RHI 
had a similar value for predicting the presence of 
CAD and its complexity. They concluded that RH-
PAT would be a more useful method for evaluat-
ing vascular endothelial function in patients with 
CAD, because it is less operator-dependent and 
it is noninvasive compared with FMD. According 
to the present results, however, it is envisioned 
herein that the assessment of vascular endothelial 
functions of both conduit arteries and resistance 
vessels using the simultaneous measurement of 
FMD and RH-PAT would be more sensitive for the 
prediction of severe CAD. 
Another novel finding of the present study is 
that RHI was negatively correlated with brachial 
artery diameter at baseline as well as at the maxi-
mum response after forearm cuff deflation following 
compression in patients with FMD < 6%, whereas 
these correlations were absent in patients with 
FMD ≥ 6%. Thus, lower RHI is associated with 
larger baseline brachial artery diameter, since the 
change in vessel diameter at maximum response 
after forearm cuff deflation was small in cases 
with low FMD. This result suggests that reactive 
hyperemic flow response of resistance vessels 
might depend on vascular remodeling in the con-
duit artery. Endothelial function contributes to the 
maintenance of vasodilator tone by endothelium-
dependent relaxing factors, including NO and EDHF 
[11, 12]. Endothelium-dependent vasodilation in the 
conduit artery is mediated mainly by NO, whereas 
the dilation of resistance vessels is mediated by 
NO and EDHF together [23]. In patients with low 
FMD, basal NO bioavailability might decrease. 
Since decreased NO bioavailability leads to positive 
vessel remodeling [24], it is postulated that EDHF 
contributes more to the endothelium-dependent 
vascular response in resistance vessels than NO 
in CAD patients with low FMD.
Figure 3. The correlation between reactive hyperemia index (RHI) and the other parameters obtained during flow-medi-
ated dilation (FMD) procedure. A. In patients with FMD ≥ 6%, there were no significant correlations; B. In patients with 
FMD < 6%, however, RHI was negatively correlated with the baseline vessel diameter and maximum vessel diameter.
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Limitations of the study
The present study has several potential limita-
tions. First, the sample size was too small to draw 
definitive conclusions. Although it was suggested 
that both low FMD and low RHI are risk factors for 
severe CAD, the number of patients in this group 
was small. In addition, a negative correlation was 
observed between RHI and brachial artery diam-
eter in patients with FMD < 6%, but not in those 
with FMD ≥ 6%. However, the number of patients 
with FMD ≥ 6% was small (n = 29), whereas there 
were 81 patients with FMD < 6%, so the absence 
of a correlation in patients with FMD ≥ 6% may be 
a type II error. Further assessment using a larger 
number of patients is needed. Second, this study 
was a cross-sectional study, and logistic regression 
analysis was used to discriminate patients with 
multi-vessel disease from others. To evaluate the 
value of FMD and RH-PAT to predict severe CAD, 
a prospective observational study is required. Fi-
nally, the mechanism for correlation between RHI 
and brachial artery diameter in patients with FMD 
< 6% may be somewhat speculative. Even consider-
ing these limitations, however, it is believed that this 
study showed important and clinically significant 
differences between FMD and RHI, and the advan-
tages of simultaneous measurement of both values.
Conclusions
From the present study it can be envisioned 
that noninvasive assessment of vascular endothe-
lial functions provide pathophysiological informa-
tion on both conduit arteries and resistance ves-
sels, and that this information is relevant to CAD. 
A unique classification by simultaneous measure-
ment of FMD and RHI would allow the prediction 
of the severity of the coronary artery lesions and 
the presence of advanced atherosclerotic CAD.
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